Where the EV-ICD fits
For years, patients who needed an ICD really had two choices: a transvenous ICD, with a lead inside the heart that could do everything (sense, shock, pace, ATP), or a subcutaneous ICD, with no lead in the heart at all but no pacing and no ATP. The transvenous system was the workhorse, but the lead inside the heart was the source of most long-term problems. The S-ICD solved the lead-in-heart problem but gave up ATP — a real loss for patients whose VT can be terminated painlessly without a shock.
The extravascular ICD (EV-ICD) was designed to occupy the middle ground. Its single lead sits in the substernal space — the small potential space just behind the breastbone, in front of the heart, but outside the heart and outside any blood vessel. From there it’s close enough to the heart to deliver ATP and short-term pacing, while keeping the long-term safety advantage of never entering the bloodstream.
The system currently FDA-approved for EV-ICD therapy is the Medtronic Aurora EV-ICD, paired with the Epsila EV lead. When we discuss “the EV-ICD” in clinic, that’s the device we mean.
What it can do that the S-ICD can’t
- Anti-tachycardia pacing (ATP). A quick burst of painless pacing that interrupts many VT episodes before a shock is needed. In patients whose VT is amenable to ATP, this can mean the difference between feeling nothing and feeling a shock.
- Brief pacing after a shock (post-shock pacing). If the heart pauses briefly after defibrillation — which can happen — the EV-ICD can pace through that window. The S-ICD cannot.
- Cleaner sensing. Because the lead sits closer to the heart than the S-ICD’s surface lead, the signal it sees is larger and less likely to be confused by muscle noise or unusual T-waves. Pre-implant EKG screening, required for the S-ICD, is not needed for the EV-ICD.
What it can’t do (yet)
The EV-ICD is not a long-term pacemaker. If you need ongoing bradycardia pacing for a slow heart rhythm, the substernal lead is not designed to deliver that day in and day out. It also cannot provide cardiac resynchronization for heart failure — that still requires a transvenous CRT system (CRT-D). And while early data are very encouraging, the EV-ICD has been in widespread use for a shorter time than the transvenous or subcutaneous platforms, so long-term lead performance data are still maturing.
Who is a good candidate
The EV-ICD is a strong choice for patients who:
- Need an ICD for primary or secondary prevention.
- Do not need long-term pacing or CRT.
- Want to avoid a lead inside the heart — younger patients, patients with limited venous access, dialysis patients, or patients with prior device infections.
- Would benefit from ATP — for example, patients with a history of monomorphic VT or ischemic cardiomyopathy where ATP-treatable VT is common.
For patients who clearly need pacing, a transvenous system remains the more complete solution. For patients who clearly don’t need ATP and prefer the most extra-cardiac option available, the S-ICD remains an excellent choice.
What life looks like afterward
Day to day, the EV-ICD is similar to any other ICD. Remote monitoring sends data from home automatically. The device is checked in clinic once or twice a year. The generator is similar in size and battery life to a transvenous ICD — typically 7+ years before replacement, depending on how often it’s called to act.
Healing from the implant tends to involve slightly more chest soreness than a transvenous procedure because of the substernal tunneling, but most patients describe it as manageable and short-lived. Within a few weeks, most are back to normal activity, with the same long-term restrictions around very heavy lifting and contact sports that apply to any implanted device.
How we think about choosing
When we sit down to choose among the three ICD platforms, we ask three questions. Do you need pacing now or are you likely to in the foreseeable future? If yes — transvenous. If not, would you benefit from ATP? If yes — EV-ICD is appealing. If neither pacing nor ATP is needed and you’d prefer the most extra-cardiac option — S-ICD. Anatomy, prior infections, kidney disease, vein status, and your own preferences all weigh into the final decision, and we go through them together.
Manufacturer reference
For technical specifications, indications, and the latest official information on the Aurora EV-ICD system from its maker, see Medtronic’s product page: Aurora EV-ICD on medtronic.com. (External link — content there is Medtronic’s and may be technical.)